Clinical Trial

First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC108.
Trial Details
NCT Number NCT07700160
Lead Sponsor VelaVigo Bio Inc
Conditions Advanced Solid Tumors
Enrollment 230 participants
Start Date 2026-07-13
Primary Completion 2029-07-07 (estimated)
Study Completion 2029-09-17 (estimated)
Updated on ClinicalTrials.gov 2026-07-13